ClinicalTrials.gg
CompletedNCT00556283ODS IIUpdated Dec 18, 2013

RCT: STARR vs Biofeedback

A Phase 4 interventional study of STARR and Biofeedback in Gastric Outlet Obstruction, Rectocele and Intussusception, sponsored by Ethicon Endo-Surgery (Europe) GmbH. Completed at 9 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Ethicon Endo-Surgery (Europe) GmbH (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study aimed to evaluate the safety and symptomatic outcomes achieved with Stapled Transanal Rectal Resection (STARR) compared to biofeedback training in patients with obstructed defecation syndrome (ODS).

02

Conditions studied

  • Gastric Outlet Obstruction
  • Rectocele
  • Intussusception
  • Anismus

Keywords

  • outlet obstruction
  • rectocele
03

In context

Gastric Outlet Obstruction

38 studies on the registry are indexed under Gastric Outlet Obstruction; 14 are open to participants now.

This study's enrollment of 121 is above the median of 69 across 28 interventional studies indexed under Gastric Outlet Obstruction.

Browse Gastric Outlet Obstruction studies →

Lead sponsor

Ethicon Endo-Surgery (Europe) GmbH is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients >18 years old
  2. Able to comprehend, follow, and provide written .
  3. Minimum ODS Score of seven at screening.
  4. Negative pregnancy test, by urine.
  5. 'Obstructed' defecation requiring straining/digitation as presenting lead symptom.
  6. Adequate external sphincter on rectal digital examination.
  7. Evidence of anterior rectocele and/or rectal intussusception on dynamic defecography. (Note: dynamic defecography taken within 12 months will be acceptable)
  8. Willingness to comply with study requirements including follow-up visits

Exclusion criteria

Exclusion Criteria:

Evidence of external sphincter injury associated with incontinence.

  1. Enterocele at rest- requiring surgery.
  2. Faecal incontinence (soiling and faecal urgency is admissible).
  3. Any anterior defect, colpocele or cystocele requiring a combined surgical approach.
  4. Physical or psychological condition which would impair participation in the study.
  5. Participation in any other device or drug study within 90 days prior to enrollment.
  6. Planned participation in any other device study during the timeframe of this study.
  7. General for surgery.
  8. Previous transanal surgery for ODS.
  9. subjects
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    1

    STARR

    Device: STARR

  • Active comparator
    2

    Biofeedback

    Behavioral: Biofeedback

Interventions

  • DeviceSTARR

    Stapled Trans-Anal Rectal Resection for the treatment of ODS

  • BehavioralBiofeedback

    electromyographic-based treatment sessions

06

What researchers measure

Primary outcomes

  1. ODS total score

    Time frame: 12 months

Secondary outcomes

  1. PAC-QoL score

    Time frame: 12 months

07

Study locations

9 sites
  • Chirurgie Proctologique
    Besancon, 25000, France
  • Clinique des Cèdres
    Cornebarrieu, 31700, France
  • Groupe Hospitalier Diaconesses Croix Saint-Simon
    Paris, 75012, France
  • Hopital Bagatelle
    Talence, 33401, France
  • CHU Purpan
    Toulouse, 31055, France
  • Ospedale S. Giuseppe
    Milan, 20123, Italy
  • Ospedale "Franchini" di Montecchio Emilia
    Montecchio Emilia, 42027, Italy
  • Ospedale Santa Maria degli Angeli
    Pordenone, 33170, Italy
  • Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00556283
Collaborators
Aysgarth Statistics, Physicians World GmbH
First posted
Nov 9, 2007
Start date
Feb 2004
Completion
May 2007
Last update
Dec 18, 2013

Study contacts

Paul A Lehur, MD
principal investigator · Institut des Maladies de l'Appareil Digestif (IMAD), University Hospital of Nantes, 1 place A Ricordeau, F-44093 Nantes Cedex 01
Goran Ribaric, MD, PhD
study director · Ethicon Endo-Surgery (Europe) GmbH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion